Our life science clients aim to maximise the potential of new and existing technologies; a specialism that demands an equally specialist legal adviser. That’s exactly what our team looks to provide, offering significant sector experience in pharmaceutical, healthcare and biotech.
Our clients represent all aspects of the life sciences community, including university spin-outs, entrepreneurs and multi-national corporations operating across drug discovery and clinical research to contract manufacturing and product development. The technologies our clients work with include pharmaceutical products, diagnostic tests and medical and dental devices at all stages of development.
Click here to see our Life Sciences 2012 brochure.
Click here to see our Shepherd and Wedderburn Life Sciences Webinar Series 2012-2013. Click here to register.
Biocompatibles International plc
Acting for Biocompatibles International, a Main Market listed medical technology company valued at £177 million, on its recommended acquisition by BTG plc.
Biocompatibles International plc
Advising Biocompatibles International in relation to the acquisition of cancer diagnostic assets and related IP of Astron Clinica Limited (in administration), a reorganisation of reserves, including a £49 million court approved cancellation of share premium account, to enable the company to pay its first dividend, and IP licensing.
Centeo Biosciences Limited
Advised Centeo Biosciences in relation to its formation, subsequent rounds of funding and commercial agreements to assist the launch and development of its life sciences products globally.
MedImmune
Acted as primary advisor to MedImmune for all legal work relating to worldwide clinical trial activities outside of the Americas for this global leading biotechnology company specialising in antibody technology which is itself the subsidiary of one of the world’s largest innovative pharmaceutical companies.
ProStrakan Group plc
Acted for ProStrakan Group plc on various fundraisings and M&A transactions (including the company's £180 million merger with Proskelia BV) as well as its subsequent £187 million London main market IPO raising £40 million through a global offering.
Scottish Enterprise
We continue to work for Scottish Enterprise in relation to a $80 million Translational Medicine Research Collaboration with Wyeth.
Scottish National Blood Transfusion Service
Advised the Scottish National Blood Transfusion Service on the spin out of Alba Bioscience, a major bio-manufacturing organisation, including advice on identification of required IP and cell lines, technology transfer and supply agreements.
Wyeth
Acted for the leading pharmaceutical and healthcare product company. Instructions include advising on an R&D agreement with a structure to protect IP in the event of insolvency.
Shepherd and Wedderburn is pleased to be hosting at its London offices the BioIndustry Association (BIA) Women in Networking event on 28 May 2013. The evening workshop is part of the BIA’s “Poised for Success - a series of evening …
This webinar, which was run on 30 April, provides an overview of some recent patent cases and changes to the relevant patent law regimes that are of particular interest to the life sciences sector. Topics covered include the unitar…
This seminar, run on 9th April by John Schmidt looks at the uncertainty created by the current ongoing investigations and court cases both in Europe and the US and discusses how to deal with the uncertainty pending the final determi…
Connect with us: